- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit - At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX...
Hence then, the article about data published in the new england journal of medicine confirm the long term durability and safety of hemgenix etranacogene dezaparvovec drlb over five years was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years )
Also on site :
- Asia rolls out four-day weeks and work-from-home as emergency measures to solve a fuel crisis caused by Iran war
- Bruce Springsteen, Tom Waits and Others Remember Shane MacGowan With Tribute Album ‘20th Century Paddy’
- Selena Quintanilla’s Sister Sues Shein Over Knockoff Merch Bearing Late Singer’s Likeness